Drug profile · INN
sorafenib
NEXAVAR
sorafenib (NEXAVAR) is a vascular endothelial growth factor receptor inhibitor. Associated with Bayer Australia Ltd.
EMA: approved TGA: approved NMPA: clinical trials Antineoplastic and immunomodulating agents (L01) L01EX02
Patents linked 3
Pipeline programs 12
News articles 0
Drug details — sorafenib
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 3
- Programs
- 12
- Data quality
- 0.83
Quick answer
sorafenib (NEXAVAR) is a vascular endothelial growth factor receptor inhibitor. Associated with Bayer Australia Ltd.
Key facts
INN sorafenib
Brand NEXAVAR
Mechanism Vascular endothelial growth factor receptor inhibitor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01EX02
Originator Bayer Australia Ltd
Mechanism of action
Vascular endothelial growth factor receptor inhibitor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is sorafenib?
sorafenib (NEXAVAR) is a vascular endothelial growth factor receptor inhibitor. Associated with Bayer Australia Ltd.
What is the brand name for sorafenib?
NEXAVAR is a marketed brand name for sorafenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.